Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer

Hofheinz, R.D.; Heinemann, Volker; Weikersthal, Ludwig Fischer von; Laubender, Rüdiger P.; Gencer, Deniz; Burkholder, Iris; Hochhaus, Andreas; Stintzing, Sebastian

doi:10.1038/bjc.2012.434

Cited by 40 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, a recent analysis of patients from the AIO's KRK-0104 trial and the Mannheim rectal cancer trial found that capecitabine-related hand-foot skin reactions were associated with an improved OS (75.8 vs 41.0 months; P=.001; HR, 0.56). 122 The addition of bevacizumab is an option if CapeOx is chosen as initial therapy. 38,113 With respect to the treatment of metastatic disease with bevacizumab-containing regimens or chemotherapy without an additional biologic agent, the consensus of the panel is that FOLFOX and CapeOx can be used interchangeably.…”

Section: -108mentioning

confidence: 99%

Colon Cancer, Version 3.2014

Benson¹,

Venook²,

Bekaii‐Saab³

et al. 2014

J Natl Compr Canc Netw

209

174

View full text Add to dashboard Cite

OverviewColorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2013, an estimated 102,480 new cases of colon cancer and approximately 40,340 cases of rectal cancer will occur. During the same year, an estimated 50,830 people will die of colon and rectal cancers combined. AbstractThe NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference. (J Natl Compr Canc Netw 2014;12:1028-1059 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

Section: -108mentioning

confidence: 99%

Colon Cancer, Version 3.2014

Benson¹,

Venook²,

Bekaii‐Saab³

et al. 2014

J Natl Compr Canc Netw

209

174

View full text Add to dashboard Cite

show abstract

“…In addition, women reporting either joint or vasomotor symptoms had a significant decrease in recurrence compared with those reporting neither symptom in adjuvant endocrine therapy 13) . Furthermore, among patients with colorectal cancer receiving capecitabine, those who developed HFS had improved PFS/DFS (29.0 vs. 11.4 months; p=0.015, HR 0.69) and OS (75.8 vs. 41.0 months; p=0.001, HR=0.56) 16) . This is the first report about the association of HFS and efficacy in MBC treated with S-1.…”

Section: Discussionmentioning

confidence: 99%

“…Skin-reaction of molecular-targeting therapy correlates with the anti-tumor effect 14,15) . HFS due to capecitabine also affects survival in patients with metastatic colorectal cancer 16,17) and is associated with efficacy for breast cancer 18) . We retrospectively evaluated the potential association of HFS and survival in patients with MBC receiving S-1.…”

Section: Introductionmentioning

confidence: 99%

S-1-associated hand-foot syndrome as a prognostic factor in patients with metastatic breast cancer

Hirano

Hattori

Inoue

et al. 2015

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

Purpose: S-1, an orally administered fluorinated pyrimidine (FP), is reported to be effective for the treatment of metastatic breast cancer (MBC). Although capecitabine, another oral FP, is widely accepted as the third-line chemotherapy for MBC, many patients treated with capecitabine suffer from hand-foot syndrome (HFS). HFS also affects survival in patients with metastatic colorectal and breast cancer. We retrospectively evaluated the potential association of HFS and survival in patients with MBC receiving S-1. Methods: Forty-four patients with MBC treated with S-1 between 2005 and 2012 were analyzed. S-1 was administered at a standard dose of 50 mg/body twice daily for 4 weeks, followed by a 2-week interval. Partly, the drug was administered for 2 weeks, followed by a one-week interval. Trastuzumab (2 mg/kg/week) was added to the regimen for HER2-positive patients. Results:The median follow-up period was 25.8 months and 12 patients (27.3%) developed HFS. Grade (G) 1 HFS was observed in 9 patients (20.5%) and G2 in 3 patients (6.8%). No G3/4 HFS was observed. Baseline demographic characteristics were comparable between the HFS and non-HFS patient groups. The HFS group showed a superior response rate (50.0% vs. 9.4%; P=0.0046), and improved median PFS (9.8 vs. 4.7 months; log-rank P=0.0446) and OS (51.5 vs. 17.5 months; logrank P=0.0196). In multivariate analysis, HFS is the only and independent prognostic factor (HR 2.93; 95% CI, 1.12 to 9.27; P=0.0269) of OS. Conclusion: HFS observed in patients with S-1 not only correlates with an antitumor effect, but is also an independent prognostic factor.

show abstract

“…Six cycles of capecitabine were received by all treated patients; with the exception of gastrointestinal toxicity and higher rates of hand-foot skin reactions, capecitabine was well tolerated [9] ( Table 3). The improvements of treatment adherence and the low toxicity permitted our patients to resume their work again.…”

Section: Discussionmentioning

confidence: 99%

Work Productivity and Activity Impairment in Colorectal Cancer Patients Treated with Capecitabine

Malaguarnera¹,

Pennisi²,

Grosso³

et al. 2013

JCT

View full text Add to dashboard Cite

Background: The employment status of workers with cancer has important implications for impairment of intimate and family relationships and for economic, social and psychological health. The aim of the present study was to evaluate the effect of chemotherapy with capecitabine in patients with colorectal cancer on work productivity and daily activity. Methods: 30 patients with primary diagnosis of stage III colorectal cancer were enrolled for our study. All patients received capecitabine twice daily at a cumulative dose of 2500 mg/m 2 on days 1 -14 and repeated on day 22. Work productivity was determined using the WPAI questionnaire. Results: We observed a significant increase in absenteeism after 1 cycle, after 6 cycles of therapy and at follow-up (p < 0.001). On the other hand, presenteeism, work productivity loss and daily activity impairment, increased after 1 cycle and 6 cycles of therapy, but we could not find statistically different significances. Conclusions: Colorectal cancer diagnosis and treatment are associated with frailty and vulnerability. Chemotherapy with capecitabine may result in negative consequences for job performance.

show abstract

Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer

Cited by 40 publications

References 19 publications

Colon Cancer, Version 3.2014

Colon Cancer, Version 3.2014

S-1-associated hand-foot syndrome as a prognostic factor in patients with metastatic breast cancer

Work Productivity and Activity Impairment in Colorectal Cancer Patients Treated with Capecitabine

Contact Info

Product

Resources

About